期刊
EUROPEAN JOURNAL OF NUCLEAR MEDICINE
卷 28, 期 9, 页码 1421-1429出版社
SPRINGER
DOI: 10.1007/s002590100502
关键词
somatostatin receptor subtypes; imaging; therapy; DTPA; DOTA
In vivo somatostatin receptor-mediated scintigraphy has proven to be a valuable method for the visualisation of neuroendocrine tumours and their metastases. A new application is the use of radiolabelled analogues for somatostatin receptor-mediated therapy. This paper presents a review on the basic science, historical background and current knowledge of somatostatin receptor subtypes and their expression in neuroendocrine tumours. New somatostatin analogues, new chelators, new radionuclides and combinations thereof are also discussed. Due attention is given to limitations and future perspectives of somatostatin receptor-mediated imaging and therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据